VF
NBIX icon

VitalStone Financial’s Neurocrine Biosciences NBIX Stock Holding History

VitalStone Financial’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$2.3K Sell
20
-39
-66% -$5.35K ﹤0.01% 379
2024
Q2 		$8.12K Buy
+59
New +$8.09K 0.01% 276

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VitalStone Financial's NBIX Position: Q3 2024 in Review

VitalStone Financial reduced its Neurocrine Biosciences (NBIX) stake by 66% in Q3 2024, selling an estimated $5.35K and leaving 20 shares worth $2.3K. The position accounts for ﹤0.01% of the portfolio, ranked #379.

VitalStone Financial first reported a position in NBIX in Q2 2024 and has held it in 2 quarters since. The position peaked at $8.12K in Q2 2024. 575 funds tracked by Wall St. Rank hold NBIX as of Q3 2024.

  • VitalStone Financial held 20 shares of Neurocrine Biosciences worth $2.3K as of Q3 2024.
  • VitalStone Financial sold 39 Neurocrine Biosciences shares in Q3 2024, an estimated $5.35K.
  • Neurocrine Biosciences made up ﹤0.01% of VitalStone Financial's portfolio in Q3 2024, its #379 holding.
  • VitalStone Financial first reported a position in Neurocrine Biosciences in Q2 2024 and has held it in 2 quarters since.
  • VitalStone Financial's Neurocrine Biosciences position peaked at $8.12K in Q2 2024.
  • 575 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2024.

Based on VitalStone Financial's 13F filing for Q3 2024, filed 11 Oct 2024.